ALDOB influences β-cell insulin secretion through modulating GLP-1R signaling in type 2 diabetes

Inside the human body, tiny clusters of cells called islets act as the command center for blood sugar control. Within these clusters, specialized workers known as beta cells are responsible for releasing insulin, the hormone that allows the body to use sugar for energy. In a healthy person, when blood sugar rises after a meal, these beta cells sense the change and release just the right amount of insulin to bring levels back to normal. However, in type 2 diabetes, this system begins to fail. The cells either stop making enough insulin or become unable to respond to the body's needs, leading to dangerously high blood sugar levels that damage organs over time. For decades, scientists have understood the basic mechanics of how beta cells work, but the specific reasons why they fail in diabetes have remained a mystery. Recent research has focused on how these cells process sugar and how they communicate with other signals in the body to decide when to release insulin.

A new study led by researchers at the City University of Hong Kong and several institutions in China has uncovered a surprising mechanism that explains why beta cells sometimes stop working properly. The team discovered that a specific protein, which was previously thought to be just a helper in breaking down sugar, actually plays a critical role in controlling the cell's ability to release insulin. When this protein is missing or altered, the beta cells lose their ability to respond to signals that tell them to work, even though the cell's basic energy production remains intact. This finding challenges the old view that the failure of beta cells is solely due to a lack of energy or direct damage, pointing instead to a complex internal switch that gets stuck in the "off" position.

The researchers began by looking at the islets from people with type 2 diabetes and from mice that had developed the disease. They found that one specific version of a protein called aldolase, known as ALDOB, was present in much higher amounts than usual. In the past, scientists believed that aldolase was simply an enzyme, a tool that helps break down sugar molecules to create energy. The team suspected that because ALDOB was so abundant in diabetic cells, it might be the key to understanding the disease. To test this, they created mice that were genetically engineered to lack ALDOB specifically in their beta cells. They expected that if ALDOB was just a helper for energy, removing it would simply make the cells weaker. Instead, they found something paradoxical: the mice without ALDOB had severe trouble releasing insulin, even when they were eating a normal diet. This suggested that ALDOB was doing something far more important than just helping to digest sugar; it was acting as a regulator for the cell's communication system.

To understand how this protein worked, the scientists dug deeper into the cell's internal machinery. They discovered that ALDOB does not regulate insulin release by breaking down sugar. Instead, it interacts with another protein called IGFBP5. Under normal conditions, ALDOB holds IGFBP5 in the main part of the cell, keeping it from moving into the nucleus, which is the control center where genes are read. When ALDOB is missing, IGFBP5 is free to travel into the nucleus. Once inside, it acts like a switch that turns up the volume on a gene called GNAI2. This gene produces a protein that effectively silences the signals telling the beta cell to release insulin. It is as if the cell has a radio that receives a signal to start working, but without ALDOB, the volume knob for the "stop" signal gets turned all the way up, drowning out the "start" command. This mechanism explains why the cells fail to release insulin even when they have plenty of sugar to process.

The study also revealed that this problem gets worse in the context of diabetes. When the researchers fed the mice a diet high in fat and sugar to mimic modern human eating habits, the lack of ALDOB led to a rapid and severe decline in insulin production. The cells became unable to respond to the body's needs, and the mice developed symptoms of diabetes much faster than those with normal levels of the protein. Interestingly, the researchers found that in people with type 2 diabetes, the number of beta cells that had this specific problem—low ALDOB and high IGFBP5—was significantly higher than in healthy people. This suggests that the body might be trying to compensate for high blood sugar by producing more ALDOB, but in some cells, this system breaks down, leading to a state where the cells can no longer do their job.

Perhaps the most promising part of the discovery is how it opens a new door for treatment. The researchers found that the protein GNAI2, which was turned on by the rogue IGFBP5, is also a target for a class of drugs called GLP-1 receptor agonists. These drugs are currently used to treat diabetes because they help the body release more insulin. However, over time, the body can become less sensitive to these drugs, a phenomenon known as desensitization. The study showed that by blocking the activity of GNAI2, the researchers could restore the cell's ability to respond to these drugs. In experiments, combining a drug that blocks GNAI2 with standard diabetes medication resulted in a much stronger insulin release than using the standard medication alone. This suggests that targeting this specific internal pathway could help overcome the resistance that patients often develop to current treatments.

The findings also clarified what this protein is not. The researchers tested whether the loss of ALDOB simply meant the cells had less energy. They found that the cells still produced enough energy to function, and that the problem was purely in the signaling pathway. They also tested a version of the protein that could not break down sugar but could still interact with other proteins, and found that this version could still rescue the cells. This confirmed that the protein's role in insulin release is separate from its job in sugar metabolism. The study provides a clear picture of a specific chain of events: the loss of ALDOB allows IGFBP5 to enter the nucleus, which turns on GNAI2, which then shuts down the insulin release signal.

This research changes the way scientists think about beta cell failure. It moves the focus from a simple lack of fuel to a complex breakdown in the cell's internal communication network. By identifying the specific proteins involved in this process, the study offers a new target for future therapies. Instead of just trying to force the cells to work harder, doctors might one day be able to fix the broken switch that is telling them to stop. The work highlights that even in a disease as common as type 2 diabetes, there are still hidden mechanisms waiting to be discovered, and that understanding these tiny molecular interactions could lead to more effective ways to manage the condition for millions of people.